NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ImmunAbs Inc.

ImmunAbs Inc.

Private
SeoulHealthcare & Life Scienceshttp://immunabs.com/

Last Round

Grant

Jan 31, 2024

Total Funding Raised

$34.98M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ImmunAbs Inc. is a biotechnology company that develops novel antibody therapeutics for autoimmune diseases, diabetic retinopathy, and metabolic syndrome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

monoclonal antibodiesantibody discoverybiotech R&Ddrug developmenttherapeutic candidatesphage displaysingle B-cell cloningclinical-stage biotechdrug licensingbiotech platformdrug discoverywet-labbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunAbs Inc. Comps

Public and private peers based on sector, stage, and business model.

ImmunAbs Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ImmunAbs Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 31, 2024
Series BNov 30, 2022
GrantNov 1, 2021
Series ASep 30, 2021

Key People

Founding team and executive leadership

Dongjo Kim

Chief Executive Officer

Executive Team

ImmunAbs Inc. Investors

Notable investors and investment history

ImmunAbs Inc. investors
InvestorRounds
D3 Jubilee PartnersSeries B
Seoul Investment PartnersSeries B, Series A
CKD Venture CapitalSeries B
Korea Drug Development FundGrant
Alpen RoutePre Seed
LogInvestmentPre Seed
DS Asset ManagementPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 482% MoM.

  • Nov 30, 2022

    $9.56M round with participation from CKD Venture Capital and Daekyo Investment.

ImmunAbs Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImmunAbs Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmunAbs Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul
Employee Range12
Year Founded2017
Last FundingJan 31, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.